Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Malignes Mesotheliom

  • Chapter
Therapiekonzepte Onkologie

  • 68 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson M, Olsen JH (1985) Trend and distribution of mesothelioma in Denmark. Br J Cancer 51:699–705

    Article  Google Scholar 

  2. Hinds MW (1978) Mesothelioma in the United States. Incidence in the 1970s. J Occup Med 20:469–471

    Article  PubMed  CAS  Google Scholar 

  3. Silverberg E (1985) Cancer statistics. CA 35:19–35

    PubMed  CAS  Google Scholar 

  4. Antman K, Corson JM (1985) Benign and malignant pleural mesothelioma. Clin Chest Med 6:127–140

    PubMed  CAS  Google Scholar 

  5. Brenner J, Sordillio PP, Magill GB (1981) Malignant peritoneal mesothelioma: a review of 25 patients. Am J Gastroenterol 75:311–313

    PubMed  CAS  Google Scholar 

  6. Rogers A, Leigh J, Berry G, Ferguson D, Mulder H, Ackad M (1993) Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. Rev Respir Dis 148:25–31

    Article  Google Scholar 

  7. Chao C, Lund L, Zinn K, Aust A (1994) Iron mobilization from crocidolite asbestos by humanlung carcinoma cells. Biochem Biophys 314:384–391

    Article  CAS  Google Scholar 

  8. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K (1995) Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 55:2981–2983

    PubMed  CAS  Google Scholar 

  9. Oels HC, Harrison EG, Carr DT, Bernatz PE (1971) Diffuse malignant mesothelioma of the pleura: a review of 37 cases. Chest 60:564–570

    Article  PubMed  CAS  Google Scholar 

  10. Said IW, Nash G, Lee M (1982) Immunoperoxidase localisation of keratin, proteins, carcinoembryonic antigen, and factor VIII in adenomatoid tumors: evidence for a mesothel derivation. Hum Pathol 13:1106–1108

    Article  PubMed  CAS  Google Scholar 

  11. Warhol MJ, Hickey WF, Corson JM (1982) Malignant mesothelioma: ultra-structional distinction from adenocarcinoma. Am J Surg Pathol 6:307–314

    Article  PubMed  CAS  Google Scholar 

  12. lones JSP, Lund C, Planteydt HT et al. (1985) Colour atlas of mesothelioma. MTP Press Limited

    Google Scholar 

  13. Butchart EG, Ashcroft T, Barnsley WA, Holden MP (1976) Pleuropneumon-ectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax 31:15–24

    Article  PubMed  CAS  Google Scholar 

  14. Mattson K (1982) Natural history and clinical staging of malignant mesothelioma. Eur J Resp Dis 63:S 124

    Google Scholar 

  15. TNM-Klassifikation maligner Tumoren, 5. Auflage (1997) In: Wittekind Ch, Wagner G (Hrsg), Springer-Verlag

    Google Scholar 

  16. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, O’Sullivan B, Sobin LH, Yarbo JW (eds) (1997) AJCC-Cancer Staging Manual, 5th edn. Lippincott, Philadelphia

    Google Scholar 

  17. Meerbeeck JP (1994) Prognostic factors in malignant mesothelioma: where do we go from here. Eur J Resp Dis 7:1029–1031

    Google Scholar 

  18. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M (1984) Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39:255–259

    Article  PubMed  CAS  Google Scholar 

  19. Alberts AS, Falkson G, Gaedhals L, Vorobiof DA, van der Merwe CA (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527–535

    PubMed  CAS  Google Scholar 

  20. Adams VI, Krishnan UK, Muhm JR, Jett JR, Ilstrup DM, Bernats PE (1986) Diffuse malignant mesothelioma of pleura. Cancer 58:1540–1551

    Article  PubMed  CAS  Google Scholar 

  21. Antman K, Shemin R, Ryan L et al. (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over 2 decades, 1965–1985. J Clin Oncol 6:147–153

    PubMed  CAS  Google Scholar 

  22. Hillerdal G (1983) Malignant mesothelioma 1982: a review of 4710 published cases. Br J Dis Chest 77:321–343

    Article  PubMed  CAS  Google Scholar 

  23. Ruffie P, Feld R, Minkin S et al. (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7:1157–1168

    PubMed  CAS  Google Scholar 

  24. van Gelder T, Damhuis RAM, Hoogsteden HC (1994) Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 7:1035–1038

    PubMed  Google Scholar 

  25. Grant DC, Seltzer SE, Antman K, Finnberg HJ, Koster K (1983) Computed tomography of malignant pleural mesothelioma. J Comput Assit Tomogr 7:626–632

    Article  CAS  Google Scholar 

  26. Maasilta P, Vehmas T, Kivisaari L, Tammilehto L, Mattson K (1991) Correlations between findings at computed tomography and at thorascopy/thoracotomy/ autopsy in pleural mesothelioma. Eur J Resp Dis 4:952–954

    CAS  Google Scholar 

  27. Sugarbaker DJ, Heher EC, Lee Th et al. (1991) Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 102:10–15

    PubMed  CAS  Google Scholar 

  28. Sugarbaker DJ, Mentzer S, DeCamp M, Lynch TJ, Strauss GM (1993) Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 103:377s-381s

    Article  PubMed  CAS  Google Scholar 

  29. Sugarbaker DJ, Strauss GM, Lynch TJ et al. (1993) Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 11:1172–1178

    PubMed  CAS  Google Scholar 

  30. Brenner J, Sordillio PP, Magill GB, Galbey RB (1982) Malignant mesothelioma of the pleura. Review of 123 patients. Cancer 49:2431–2435

    Article  PubMed  CAS  Google Scholar 

  31. Krarup-Hansen A, Hansen HH (1991) Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 28:319–330

    Article  PubMed  CAS  Google Scholar 

  32. Zeng L, Monnet I, Boutin C et al. (1993) In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 55:515–520

    Article  PubMed  CAS  Google Scholar 

  33. Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD (1984) Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 44:1688–1692

    PubMed  CAS  Google Scholar 

  34. Chahinian AP, Antman K, Goutsou M et al. (1993) Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559–1565

    PubMed  CAS  Google Scholar 

  35. World Health Organisation (1979) WHO handbook for reporting results of cancer treatment

    Google Scholar 

  36. Lee YL, Wesley RA (1981) Statistical contributions to phase II trials in cancer: interpretation, analysis and design. Semin Oncol 8:403–416

    PubMed  CAS  Google Scholar 

  37. Magri MD, Foladore S, Veronesi A et al. (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 3:237–238

    PubMed  CAS  Google Scholar 

  38. Solheim O, Saeter G, Finnanger A, Stenwig A (1992) High-dose methtrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–960

    Article  CAS  Google Scholar 

  39. Pennucci MC, Ardizzoni A, Pronzato P et al. (1997) Combined cisplatin, doxorubicin and mitomycin for the treatment of advanced pleural mesothelioma. Cancer 79:1897–1902

    Article  PubMed  CAS  Google Scholar 

  40. Meerbeeck JP, Baas P, Debruyne C et al. (1997) Gemcitabine in malignant pleural mesothelioma: A phase II study. Lung Cancer 18:Suppl. 1:17 (Abstract)

    Article  Google Scholar 

  41. Stewart DJ, Gertler SZ, Tomiak A, Shamji F, Goel R, Evans WK (1994) High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 11:251–258

    Article  PubMed  CAS  Google Scholar 

  42. Krarup-Hansen A (1994) Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer 11:305–308

    Article  PubMed  CAS  Google Scholar 

  43. Middleton G, Verill M, Priest K, Spencher L, O’Brien M, Smith I (1997) Good symptom relief with palliative MVP (mitomycin C, vinblastine, cisplatin). Lung Cancer 18:22 (Abstract)

    Article  Google Scholar 

  44. Stewart DJ, Gertler SZ, Shamji F et al. (1997) High dose doxorubicin, cisplatin and tamoxifen vs mesothelioma. Lung Cancer 18:49 (Abstract)

    Google Scholar 

  45. Sørrensen PG, Bach F, Bork E, Hansen HH (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma. Cancer Treat Rep 69:1431–1432

    Google Scholar 

  46. Bautin C, Viallat JR, Astoul P (1990) Treatment of mesothelioma with interferon gamma and interleukin 2. Rev Pneumol Clin 46:211–215

    Google Scholar 

  47. Bautin C, Viallat JR, van Zandwijk N et al. (1991) Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033–2037

    Article  Google Scholar 

  48. von Hoff T, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE (1990) Phase-II evaluation of recombinant interferon-β (IFN-β ser) in patients with diffuse mesothelioma: a southwest oncology group study. J Interferon Res 10:531–534

    Article  Google Scholar 

  49. Robinson BWS, Manning LS, Bowman RV et al. (1993) The scientific basis for the immunotherapy of human malignant mesothelioma. Eur Respir Rev 3:195–198

    Google Scholar 

  50. Boutin C, Viallat JR, van Zandwijk N et al. (1991) Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 67:2033–2037

    Article  PubMed  CAS  Google Scholar 

  51. Boutin C, Nussbaum E, Monnet I et al. (1994) Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74:2460–2467

    Article  PubMed  CAS  Google Scholar 

  52. Mulatero C, Penson R, Papamichael D, Gower N, Evans M Rudd R (1997) A phase II study of interleukin-2 in malignant pleural mesothelioma. Lung Cancer 18:18

    Article  Google Scholar 

Download references

Authors
  1. A. Krarup-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. H. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Krarup-Hansen, A., Hansen, H.H. (1998). Malignes Mesotheliom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation